6 Results for "

RNA interference agents

" in MedChemExpress (MCE) Product Catalog:
Products (6)

6 Results for "RNA interference agents" in MCE Product Catalog:

1
1 Cited Publications
Cat. No.: HY-132613
CAS No.: 1834612-06-4
Purity:  99.21%
Lumasiran sodium, an investigational RNA interference (RNAi) therapeutic agent, reduces hepatic oxalate production by targeting glycolate oxidase. Lumasiran sodium reduces urinary oxalate excretion, the cause of progressive kidney failure in primary hyperoxaluria type 1 (PH1) .
loading...
    loading...
Cat. No.: HY-145720
CAS No.: 1639264-46-2
Synonyms: ALN-CC5
Cemdisiran (ALN-CC5) is an N-acetylgalactosamine-conjugated RNAi agent and also a complement component C5 inhibitor. Cemdisiran targets C5 mRNA, cleaves C5 mRNA via the endogenous RNA interference pathway, and inhibits the production of C5 protein in the liver. Cemdisiran exerts a dose-dependent inhibitory effect on total C5 concentrations in cynomolgus monkeys. When used in combination with Pozelimab (HY-P99786) in cynomolgus monkeys, Cemdisiran achieves a more sustained and complete inhibitory effect on complement activity. Cemdisiran can be used in the research of paroxysmal nocturnal hemoglobinuria and other complement-mediated diseases .
loading...
    loading...
Cat. No.: HY-132590A
Purity:  93.16%
Synonyms: ALN-TTRSC sodium
Revusiran (ALN-TTRSC) sodium is an RNA interference agent targeting the mRNA of transthyretin (Transthyretin, TTR). Revusiran sodium mediates sequence-specific degradation of TTR mRNA through RNA interference, reduces the synthesis of TTR protein, binds to GalNAc ligands, and is taken up by hepatocytes via the asialoglycoprotein receptor. Revusiran sodium exhibits favorable nonclinical safety profiles. Revusiran sodium can be used in studies related to transthyretin-mediated amyloidosis .
loading...
    loading...
Cat. No.: HY-145720A
Purity:  96.02%
Synonyms: ALN-CC5 sodium
Cemdisiran sodium (ALN-CC5 sodium) is an N-acetylgalactosamine-conjugated RNAi agent and also a complement component C5 inhibitor. Cemdisiran sodium targets C5 mRNA, cleaves C5 mRNA via the endogenous RNA interference pathway, and inhibits the production of C5 protein in the liver. Cemdisiran sodium exerts a dose-dependent inhibitory effect on total C5 concentrations in cynomolgus monkeys. When used in combination with Pozelimab (HY-P99786) in cynomolgus monkeys, Cemdisiran sodium achieves a more sustained and complete inhibitory effect on complement activity. Cemdisiran sodium can be used in the research of paroxysmal nocturnal hemoglobinuria and other complement-mediated diseases .
loading...
    loading...
Cat. No.: HY-132590
CAS No.: 1438322-82-7
Synonyms: ALN-TTRSC
Revusiran (ALN-TTRSC) is an RNA interference agent targeting the mRNA of transthyretin (Transthyretin, TTR). Revusiran mediates sequence-specific degradation of TTR mRNA through RNA interference, reduces the synthesis of TTR protein, binds to GalNAc ligands, and is taken up by hepatocytes via the asialoglycoprotein receptor. Revusiran exhibits favorable nonclinical safety profiles. Revusiran can be used in studies related to transthyretin-mediated amyloidosis .
loading...
    loading...
Cat. No.: HY-187051
CAS No.: 1953147-04-0
Target:  

Phosphoramidites

Research Areas:  

Metabolic Disease

AdemG Phosphoramidite is a ligand-conjugated phosphoramidite synthon. AdemG Phosphoramidite can be used for the synthesis of GalNAc-conjugated siRNA and DsiRNA for liver-targeted gene silencing .
loading...
    loading...